Stoke Therapeutics Posts -4.63 ROIC/WACC, Best Among Biopharma Peers
STOK•Stoke Therapeutics has a ROIC of -45.41% against a 9.80% WACC, yielding a ROIC/WACC ratio of -4.63. This ratio is the highest (least negative) among clinical-stage biopharma peers, surpassing Revolution Medicines’ -6.44, Gossamer Bio’s -35.84 and Atreca’s -15.46.
1. Analysis of Stoke’s ROIC and WACC
Stoke Therapeutics reported a return on invested capital of -45.41% in its latest assessment, while its weighted average cost of capital stands at 9.80%. The resulting ROIC/WACC ratio of -4.63 reflects the extent to which the company is currently investing ahead of revenue generation in its clinical trials.
2. Comparison with Peer Capital Efficiency
Within its peer group, Stoke’s ROIC/WACC ratio is the least negative, compared to Revolution Medicines (-6.44), Gossamer Bio (-35.84) and Atreca (-15.46). This relative performance indicates Stoke maintains a stronger capital efficiency profile despite the sector’s generally negative returns.
3. Investor Implications
While clinical-stage biopharma firms typically operate below cost of capital, Stoke’s comparatively higher efficiency may influence its future fundraising terms and investor confidence. Monitoring changes in ROIC and WACC will be crucial as Stoke advances its genetic disorder therapies toward commercialization.
